Grace Wong-Sarad Sells 5,165 Shares of Alector (NASDAQ:ALEC) Stock

by · The Markets Daily

Alector, Inc. (NASDAQ:ALEC – Get Free Report) insider Grace Wong-Sarad sold 5,165 shares of the business’s stock in a transaction dated Thursday, September 3rd. The shares were sold at an average price of $2.67, for a total value of $13,790.55. Following the completion of the transaction, the insider owned 109,640 shares in the company, valued at $292,738.80. This trade represents a 4.50% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Grace Wong-Sarad also recently made the following trade(s):

  • On Friday, September 4th, Grace Wong-Sarad sold 3,625 shares of Alector stock. The shares were sold at an average price of $2.51, for a total value of $9,098.75.
  • On Wednesday, September 2nd, Grace Wong-Sarad sold 656 shares of Alector stock. The stock was sold at an average price of $2.75, for a total value of $1,804.00.

Alector Stock Performance

Shares of ALEC stock traded down $0.05 during midday trading on Friday, hitting $2.46. The company had a trading volume of 496,599 shares, compared to its average volume of 882,288. The stock has a market cap of $274.68 million, a price-to-earnings ratio of -2.24 and a beta of 0.65. The company has a debt-to-equity ratio of 0.80, a current ratio of 5.26 and a quick ratio of 5.26. The company’s 50 day simple moving average is $1.89 and its 200 day simple moving average is $2.05. Alector, Inc. has a 52-week low of $1.09 and a 52-week high of $3.40.

Alector (NASDAQ:ALEC – Get Free Report) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.02. Alector had a negative return on equity of 531.03% and a negative net margin of 850.13%.The business had revenue of $3.32 million during the quarter, compared to analysts’ expectations of $1.71 million. Research analysts anticipate that Alector, Inc. will post -0.87 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ALEC has been the subject of a number of analyst reports. Weiss Ratings upgraded shares of Alector from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, August 13th. Wall Street Zen raised shares of Alector from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Three investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Alector has an average rating of “Hold” and a consensus target price of $3.62.

Check Out Our Latest Analysis on ALEC

Institutional Trading of Alector

Several hedge funds have recently modified their holdings of the business. BlackRock Inc. purchased a new stake in shares of Alector in the second quarter valued at approximately $15,774,000. Vanguard Group Inc. raised its position in Alector by 0.8% in the third quarter. Vanguard Group Inc. now owns 6,034,659 shares of the company’s stock worth $17,863,000 after acquiring an additional 46,955 shares in the last quarter. Nantahala Capital Management LLC purchased a new position in Alector in the second quarter worth $8,679,399. Foresite Capital Management IV LLC acquired a new stake in Alector in the fourth quarter valued at $6,064,000. Finally, Merck & Co. Inc. purchased a new stake in shares of Alector during the 2nd quarter worth $7,126,896. 85.83% of the stock is owned by institutional investors and hedge funds.

Alector Company Profile

(Get Free Report)

Alector is a clinical-stage biotechnology company headquartered in South San Francisco, California. Founded in 2013, the company is focused on discovering and developing immuno-neurology therapies that target the innate immune system to treat a range of neurodegenerative disorders. Alector’s approach aims to harness the body’s natural defense mechanisms to clear pathological proteins and restore neuronal function in conditions such as Alzheimer’s disease and frontotemporal dementia.

The company’s pipeline includes multiple product candidates in both preclinical and clinical stages, with lead programs AL001 and AL002 advancing in frontotemporal dementia and Alzheimer’s disease studies.

Further Reading